Ames negative; clastogenic in two in vitro assays; negative in vivo rat comet and chromosome aberration assays; not genotoxic overall
“Vadadustat was negative for mutagenicity in the Ames assay. Vadadustat yielded clastogenic activity from two in vitro assays but was negative for genotoxic activity when administered to Sprague Dawley rats in an in vivo COMET and chromosomal aberration study.”
Not carcinogenic in rasH2 transgenic mice or Sprague Dawley rats (rat exposure up to ~0.3x clinical AUC)
“Vadadustat was not carcinogenic in RasH2 transgenic mice and was not carcinogenic in Sprague Dawley rats administered vadadustat up to approximately 0.3-fold the clinical dose of 600 mg, based on AUC.”
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
No effect on fertility and not teratogenic; lower fetal and pup weights and reduced ossification at maternally toxic doses
“Vadadustat did not affect fertility or cause teratogenicity, although lower fetal weight (-7%), lower pup weight (-5% to -11%), and reduced fetal skeletal ossifications occurred at dose levels associated with maternal toxicity.”
Transient blood pressure decrease with compensatory heart rate increase (rat, dog); no meaningful hERG effect; no ECG changes
“In both rat and dog, vadadustat caused a transient decrease in blood pressure with a compensatory increase in HR. Vadadustat had no meaningful effect in the in vitro hERG assay and did not cause changes of P-QRS-T complexes in rats or dogs.”
CHO chromosomal aberration positive; GreenScreen equivocal
“Vadadustat was negative for mutagenicity (Ames assay) but positive results were obtained in the in vitro CHO assay for chromosomal aberrations and the GreenScreen assay. The positive in vitro chromosome aberration assay with CHO cells and equivocal GreenScreen assay suggested that vadadustat may be clastogenic and/or aneugenic.”
Rat peripheral blood lymphocyte chromosomal aberration and comet assays: negative
“Vadadustat exhibited clastogenic activity in vitro but was negative in the in vivo chromosomal aberration assay in peripheral blood lymphocytes and comet assay in rats. Based on the weight of evidence, vadadustat is not considered genotoxic.”
2-year rat and 6-month Tg rasH2 mouse: not carcinogenic (rat exposure ~0.3x clinical AUC)
“The carcinogenic potential of vadadustat was evaluated in a 6-month RasH2 transgenic mouse study and in a 2-year rat study. Vadadustat was not carcinogenic in RasH2 transgenic mice and was not carcinogenic in Sprague Dawley rats administered vadadustat up to approximately 0.3-fold the clinical dose of 600 mg, based on AUC.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative